MA32811B1 - Nouveaux composés - Google Patents

Nouveaux composés

Info

Publication number
MA32811B1
MA32811B1 MA33866A MA33866A MA32811B1 MA 32811 B1 MA32811 B1 MA 32811B1 MA 33866 A MA33866 A MA 33866A MA 33866 A MA33866 A MA 33866A MA 32811 B1 MA32811 B1 MA 32811B1
Authority
MA
Morocco
Prior art keywords
new compounds
compounds
relates
drug
excessive
Prior art date
Application number
MA33866A
Other languages
Arabic (ar)
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Original Assignee
Boehringer Ingemheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingemheim Internat Gmbh filed Critical Boehringer Ingemheim Internat Gmbh
Publication of MA32811B1 publication Critical patent/MA32811B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE LA FORMULE GÉNÉRALE (I) DANS LAQUELLE A, B, X, R1 À R3 SONT TELS QUE DÉFINIS DANS LA REVENDICATION 1, LESDITS COMPOSÉS ÉTANT APPROPRIÉS POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE. L'INVENTION CONCERNE ÉGALEMENT LEUR UTILISATION POUR PRÉPARER UN MÉDICAMENT AYANT LES PROPRIÉTÉS MENTIONNÉES CI-DESSUS.
MA33866A 2008-11-24 2011-05-20 Nouveaux composés MA32811B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169807 2008-11-24
EP09169654 2009-09-07
PCT/EP2009/065768 WO2010058032A2 (fr) 2008-11-24 2009-11-24 Nouveaux composés

Publications (1)

Publication Number Publication Date
MA32811B1 true MA32811B1 (fr) 2011-11-01

Family

ID=42115425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33866A MA32811B1 (fr) 2008-11-24 2011-05-20 Nouveaux composés

Country Status (26)

Country Link
US (4) US8846689B2 (fr)
EP (1) EP2367800B9 (fr)
JP (1) JP5622740B2 (fr)
KR (1) KR101710058B1 (fr)
CN (2) CN102292322B (fr)
AP (1) AP2960A (fr)
AR (1) AR074210A1 (fr)
AU (1) AU2009317170B2 (fr)
BR (1) BRPI0922801B1 (fr)
CA (1) CA2744351C (fr)
CL (1) CL2011001215A1 (fr)
CO (1) CO6511283A2 (fr)
EA (1) EA021997B1 (fr)
EC (1) ECSP11011079A (fr)
ES (1) ES2664499T3 (fr)
GE (1) GEP20146072B (fr)
IL (1) IL212814B (fr)
MA (1) MA32811B1 (fr)
MX (1) MX337116B (fr)
MY (1) MY176944A (fr)
NZ (1) NZ592925A (fr)
PE (1) PE20120034A1 (fr)
TN (1) TN2011000259A1 (fr)
TW (1) TWI491605B (fr)
UY (1) UY32259A (fr)
WO (1) WO2010058032A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012110773A1 (fr) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
EP2832734A4 (fr) 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
EP3417851B1 (fr) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Éthers d'aryle et leurs utilisations
WO2016145032A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions utilisées pour traiter l'hypertension artérielle pulmonaire
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3268362B1 (fr) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
US20230145356A1 (en) 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
KR20220107229A (ko) 2019-11-28 2022-08-02 인엑스메드 (난징) 컴퍼니 리미티드 암 치료에서 bi853520의 용도
KR20220137666A (ko) 2020-02-05 2022-10-12 인엑스메드 (난징) 컴퍼니 리미티드 Bi853520과 화학요법 약물의 병용
JP7836097B2 (ja) * 2020-08-03 2026-03-26 ▲應▼世生物科技（南京）有限公司 化合物の固体形態
WO2023020291A1 (fr) 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 Utilisation combinée de l'in10018 et de la pld
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023104151A1 (fr) 2021-12-10 2023-06-15 应世生物科技(南京)有限公司 Composition pharmaceutique pour le traitement de tumeurs et utilisation
CN118525015A (zh) 2021-12-21 2024-08-20 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
CN118574825A (zh) 2022-02-28 2024-08-30 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
JP2025520715A (ja) * 2022-06-24 2025-07-03 ▲應▼世生物科技（南京）有限公司 腫瘍を処置するための組合せ医薬及びその使用
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
EP4578449A4 (fr) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd Association pharmaceutique d'inhibiteur de fak et d'inhibiteur de microtubule et utilisation associée
CN118580221A (zh) * 2023-03-02 2024-09-03 应世生物科技(南京)有限公司 化合物的固体形式
WO2025148858A1 (fr) 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 Inhibiteur de fak et inhibiteur pan-ras

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
JP4460292B2 (ja) 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004048343A1 (fr) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
EP1598343A1 (fr) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ATE520672T1 (de) 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
CA2593482A1 (fr) 2005-01-14 2006-07-20 Neurogen Corporation Analogues de quinolin-4-ylamine a substitution heteroaryle
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
JP2009520038A (ja) * 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (fr) 2006-10-03 2008-04-10 Astrazeneca Ab Composés
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
CA2670645A1 (fr) 2006-12-19 2008-07-03 Genentech, Inc. Inhibiteurs de pyrimidine kinase
CA2702647C (fr) 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Composes a base de thiopyrimidine et ses utilisations
MX2009011199A (es) * 2007-04-16 2010-03-17 Hutchison Medipharma Entpr Ltd Derivados de pirimidina.
CA2718858A1 (fr) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Elaboration regioselective de pyrimidines substituees
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법

Also Published As

Publication number Publication date
TN2011000259A1 (en) 2012-12-17
EA201100794A1 (ru) 2012-01-30
CN102292322B (zh) 2015-11-25
ECSP11011079A (es) 2011-06-30
JP5622740B2 (ja) 2014-11-12
CN104478865B (zh) 2017-09-22
TWI491605B (zh) 2015-07-11
GEP20146072B (en) 2014-04-10
US8846689B2 (en) 2014-09-30
ES2664499T3 (es) 2018-04-19
US9676762B2 (en) 2017-06-13
US20160362404A1 (en) 2016-12-15
EP2367800A2 (fr) 2011-09-28
KR20110084551A (ko) 2011-07-25
EA021997B1 (ru) 2015-10-30
IL212814B (en) 2018-05-31
MX337116B (es) 2016-02-12
CN104478865A (zh) 2015-04-01
CA2744351A1 (fr) 2010-05-27
AP2011005706A0 (en) 2011-06-30
CA2744351C (fr) 2017-07-04
WO2010058032A3 (fr) 2010-07-15
AR074210A1 (es) 2010-12-29
JP2012509864A (ja) 2012-04-26
CL2011001215A1 (es) 2011-09-30
AU2009317170B2 (en) 2015-05-28
NZ592925A (en) 2013-04-26
TW201026682A (en) 2010-07-16
UY32259A (es) 2010-06-30
HK1160841A1 (zh) 2012-08-17
EP2367800B9 (fr) 2021-10-20
US20110288071A1 (en) 2011-11-24
AP2960A (en) 2014-08-31
BRPI0922801B1 (pt) 2021-12-21
KR101710058B1 (ko) 2017-02-24
WO2010058032A2 (fr) 2010-05-27
ES2664499T9 (es) 2022-01-03
CO6511283A2 (es) 2012-08-31
EP2367800B1 (fr) 2018-02-28
MX2011005420A (es) 2011-06-16
MY176944A (en) 2020-08-27
AU2009317170A1 (en) 2010-05-27
PE20120034A1 (es) 2012-02-19
CN102292322A (zh) 2011-12-21
IL212814A0 (en) 2011-07-31
US20150376141A1 (en) 2015-12-31
BRPI0922801A2 (pt) 2020-08-04
US20140371205A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
MA32505B1 (fr) 5-alcynyl-pyrimidines
EA201170521A1 (ru) Новые соединения
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
EA201001639A1 (ru) Композиции и способы их получения и применения
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201070422A1 (ru) Производные оксадиазола
GEP20146125B (en) Aminopyrimidines as syk inhibitors
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
MY153915A (en) Organic compounds
PH12013500152A1 (en) New aminopyrazoloquinazolines
WO2010034838A3 (fr) Nouveaux composés chimiques
MX2012002641A (es) Inhibidores de cinasa janus (jak).
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA201170344A1 (ru) Азаиндольные ингибиторы iap
IN2012DN03846A (fr)
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2010009837A (es) Tiazolil-dihidro-indazoles.